1. Tumor-Activated Benzothiazole Inhibitors of Stearoyl-CoA Desaturase.
- Author
-
Williams NS, Gonzales S, Naidoo J, Rivera-Cancel G, Voruganti S, Mallipeddi P, Theodoropoulos PC, Geboers S, Chen H, Ortiz F, Posner B, Nijhawan D, and Ready JM
- Subjects
- Animals, Benzothiazoles pharmacokinetics, Cell Line, Tumor, Cytochrome P450 Family 4 metabolism, Female, Humans, Mice, Prodrugs metabolism, Tissue Distribution, Benzothiazoles pharmacology, Enzyme Inhibitors pharmacology, Stearoyl-CoA Desaturase antagonists & inhibitors
- Abstract
A series of N -acyl benzothiazoles shows selective and potent cytotoxicity against cancer cell lines expressing cytochrome P450 4F11. A prodrug form is metabolized by cancer cells into an active inhibitor of stearoyl-CoA desaturase (SCD). Substantial variation on the acyl portion of the inhibitors allowed the identification of ( R )- 27 , which balanced potency, solubility, and lipophilicity to allow proof-of-concept studies in mice. The prodrugs were activated inside the tumor, where they can arrest tumor growth. Together, these observations offer promise that a tumor-activated prodrug strategy might exploit the essentiality of SCD for tumor growth, while avoiding toxicity associated with systemic SCD inhibition.
- Published
- 2020
- Full Text
- View/download PDF